Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma

There is an unmet need for effective biological therapies for relapsed central nervous system (CNS) lymphoma. Lenalidomide is active in activated B-cell type diffuse large B-cell lymphoma and rituximab is effective in CNS lymphoma. These observations are the basis for this first trial of an immunomo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Rubenstein, James L., Geng, Huimin, Fraser, Eleanor J., Formaker, Paul, Chen, Lingjing, Sharma, Jigyasa, Killea, Phoebe, Choi, Kaylee, Ventura, Jenny, Kurhanewicz, John, Lowell, Clifford, Hwang, Jimmy, Treseler, Patrick, Sneed, Penny K., Li, Jing, Wang, Xiaomin, Chen, Nianhang, Gangoiti, Jon, Munster, Pamela N., Damato, Bertil
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6039666/
https://ncbi.nlm.nih.gov/pubmed/29986852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017014845
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados